4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as required by Rule 18 of the AIM Rules for Companies, after it was placed into administration on 24 June 2022, when trading in the its ordinary shares were suspended clarification of the Company’s financial position.
Accordingly, the suspension will also remain in place pending announcement of the interim results in accordance with AIM Rule 18, the company said.
Further to the publication of the Joint Administrators’ Proposals on August 4 2022, the Joint Administrators continue to evaluate potential avenues to return the Company from administration and this process is ongoing. Further announcements will be made in due course.